# Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

> **NCT04418648** · PHASE2 · TERMINATED · sponsor: **Sun Yat-sen University** · enrollment: 170 (actual)

## Conditions studied

- Small Cell Lung Cancer Limited Stage

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04418648
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-01
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 170 (ACTUAL)
- **Why stopped:** Since the interim results of the ADRIATIC trial presented at the ASCO Annual Meeting in June 2024, the design of the control group is no longer consistent with current clinical practice.
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418648, "Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04418648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*